Robert Rolleri

A retrospective analysis: the development of patient reported outcome measures for the assessment of Crohn's disease activity

Reena Khanna, Guangyong Zou, Geert D’Haens et al. · Alimentary Pharmacology & Therapeutics · 2014 · 235 citations · Full text

Medicine, Pharmacotherapy, Gastroenterology +12

Efficacy and Safety of Bimekizumab in Moderate to Severe Hidradenitis Suppurativa

Sophie Glatt, Gregor B. E. Jemec, Seth Forman et al. · JAMA Dermatology · 2021 · 167 citations · Full text

Pharmacy, Internal Medicine, Pharmacotherapy +16

Efficacy and safety of bimekizumab in patients with moderate-to-severe hidradenitis suppurativa (BE HEARD I and BE HEARD II): two 48-week, randomised, double-blind, placebo-controlled, multicentre phase 3 trials

Alexa B. Kimball, Gregor B. E. Jemec, Christopher J. Sayed et al. · The Lancet · 2024 · 164 citations · Full text

Medicine, Internal Medicine, Pharmacotherapy +3

Certolizumab pegol for the treatment of chronic plaque psoriasis: Results through 48 weeks of a phase 3, multicenter, randomized, double-blind, etanercept- and placebo-controlled study (CIMPACT)

Mark Lebwohl, Andrew Blauvelt, C. Paul et al. · Journal of the American Academy of Dermatology · 2018 · 131 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +13

Budesonide Foam Induces Remission in Patients With Mild to Moderate Ulcerative Proctitis and Ulcerative Proctosigmoiditis

William J. Sandborn, Brian P. Bosworth, Salam Zakko et al. · Gastroenterology · 2015 · 106 citations · Full text

Veterinary Medicine, Immunology, Inflammation +9